Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics adds James M. Daly to board, names him to Compliance Committee

Neutral Impact 2 of 5 leadership Written later

Cytokinetics appointed James M. Daly to fill a vacant Board seat effective August 19, 2025, as a Class III director with a term expiring at the 2028 annual meeting. The Board determined he is independent, and he joins the Compliance Committee. The filing describes a routine board addition with standard director compensation and no reported related-party transactions.

Key points

  • Daly appointed to a vacant Board seat effective August 19, 2025; term expires at the 2028 annual meeting
  • Initial grant: option to purchase 27,450 shares with a grant date fair value of $700,000, vesting monthly over three years
  • Annual compensation includes a $50,000 Board retainer, a $7,500 Compliance Committee retainer, and equity grants with an aggregate fair value of $440,000

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECAug 20, 2025, 7:57 AM ET
Accession number0000950170-25-110368

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.